Article

A clinical-stage oncology compound selectively targets drug-resistant cancers

2025-11-30

Abstract excerpt

Re-evaluating existing clinical compounds can uncover previously unrecognized mechanisms that reshape a drug's therapeutic potential. The small molecule Procaspase-Activating Compound 1 (PAC-1) entered oncology testing as a proposed activator of caspase-driven apoptosis. Here, we show that PAC-1-driven cytotoxicity occurs in the absence of executioner caspase expression, demonstrating that its anti-cancer activity...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e94d986d-79b9-57c3-87bb-c25c84223586
DOI: 10.1101/2025.11.26.690878

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A clinical-stage oncology compound selectively targets drug-resistant cancersDOI 10.1101/2025.11.26.690878Read

Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein–Expressing CellsSemantic proximity Read

Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced ToxicitySemantic proximity Read

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoningSemantic proximity Read

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 InhibitionSemantic proximity Read

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducersSemantic proximity Read

Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advancesSemantic proximity Read

Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed MyeloblastsSemantic proximity Read

Metal- and metalloid-based compounds to target and reverse cancer multidrug resistanceSemantic proximity Read

Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug TargetSemantic proximity Read

Discovery of PARP1-PROTAC as novel strategy against PARP inhibitor resistance via promoting ferroptosis in mutant-p53 triple-negative breast cancerSemantic proximity Read

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesSemantic proximity Read

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.Semantic proximity Read